Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Regional and Segment Sales Breakdown
JNJ logo

Johnson & Johnson Targets Historic $100 Billion Annual Revenue Milestone

JNJ8-KFiling Date: 7/15/2026
Johnson & Johnson
Description

What this story covers

Johnson & Johnson reported record Q2 2026 sales of $25.3 billion and raised its full-year revenue guidance to $101.1 billion, driven by strong oncology and immunology growth despite significant biosimilar competition for its drug Stelara.

Story snapshot

CompanyJohnson & Johnson
TickerJNJ
VariantStandard detailed
Duration4:47
Filing type8-K
PeriodQ3 2026
IndustryHealthcare & Pharmaceuticals
Accession0000200406-26-000146
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in